Evaluation of pleural fluid human epididymis 4 (HE4) as a marker of malignant pleural effusion

Tumor Biology

Volumn 33, Issue 5, 2012, Pages 1701-1707

  Elsammak, Mohamed Y ^a,b   Attia, Adel ^a,d   Hassan, Hoda A ^a,b   Zaytoun, Taysser M ^a,c   Shorman, Mahmoud ^a   Suleman, Moosa ^a  

^a KING FAHAD SPECIALIST HOSPITAL   (Saudi Arabia)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c ALEXANDRIA UNIVERSITY   (Egypt)

^d ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Human epididymis 4 (HE4); Pleural effusion

Indexed keywords

HUMAN EPIDIDYMIS PROTEIN 4; LACTATE DEHYDROGENASE; SERUM ALBUMIN;

ADULT; ARTICLE; BREAST ADENOCARCINOMA; COHORT ANALYSIS; COLON ADENOCARCINOMA; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; IMMUNOASSAY; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURAL EFFUSION; NONHODGKIN LYMPHOMA; PLEURA EFFUSION; PLEURA FLUID; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; STOMACH CANCER;

EID: 84868111767     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0427-y     Document Type: Article

References (27)

1. Murphy MJ, Jenkinson F. Categorisation of pleural fluids in routine clinical practice: analysis of pleural fluid protein and lactate dehydrogenase alone compared with modified Light's criteria. J Clin Pathol. 2008;61:684-5.
2. Light RW, Mac Gregor MI, Luchsinger PC, Ball WC. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972;77:507-13.
3. Heffner JE, Brown LK, Barbieri CA. Diagnostic value of tests that discriminate between exudative and transudative pleural effusions. Primary Study Investigators. Chest. 1997;111:970-80.
4. Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991;4:320-4.
5. Garcia L. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol. 1994;7(3):665e8.
6. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE. Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology. 2010;42:224-8.
7. Hackbarth JS, Murata K, Reilly WM, Algeciras-Schimnich A. Performance of CEA and CA19-9 in identifying pleural effusions caused by specific malignancies. Clin Biochem. 2010;43:1051-5.
8. Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757-63.
9. Bouchard D, Morisset D, Bourbonnais Y, et al. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006;7:167-74.
10. Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768-73.
11. Kirchhoff C, Habben I, Ivell R, Krull N. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors. Biol Reprod. 1991;45:350-7.
12. Hegmans JP, Veltman JD, Fung ET, Verch T, Glover C, Zhang F, Allard WJ, T'Jampens D, Hoogsteden HC, Lambrecht BN. Aerts J Protein profiling of pleural effusions to identify malignant pleural mesothelioma using SELDI-TOF MS. Technol Cancer Res Treat. 2009;8:323-32.
13. Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torné A, Lejarcegui J, Pahisa J. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32:1087-95.
14. Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, Tognon G, Bignotti E, Tassi R, Odicino F, Caimi L, Sartori E, Santin AD, Pecorelli S, Ravaggi A. Serum human epididymis protein 4 (HE4) and Risk for Ovarian Malignancy Algorithm (ROMA) as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496-506.
15. Hynninen J, Auranen A, Dean K, Lavonius M, Carpen O, Perheentupa A, Seppanen M, Grenman S. Serum HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011;21(9):1573-8.
16. Hellström I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, Drescher C, Urban N, Hellström KE. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695-700.
17. Drapkin R, Von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-9.
18. Tokuishi K, Yamashita SI, Ohbo K, Kawahara K. Splice variant HE4-V3 expression is associated with favorable prognosis in pulmonary adenocarcinoma. Tumour Biol. 2012;33:103-9.
19. Antunes G, Neville E, Duffy J, Ali N, Pleural Diseases Group. BTS guidelines for the management of malignant pleural effusions. Standards of Care Committee, British Thoracic Society. Thorax. 2003;58 Suppl 2:ii29-38.
20. Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32-5.
21. Korczynski P, Krenke R, Safianowska A, Gorska K, Abou Chaz MB, Maskey-Warzechowska M, Kondracka A, Nasilowski J, Chazan R. Diagnostic utility of pleural fluid and serum markers in differentiation between malignant and non-malignant pleural effusions. Eur J Med Res.;14 Suppl 4:128-33.
22. Gaspar MJ, De Miguel J, García Díaz JD, Díez M. Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions. Anticancer Res. 2008;28:2947-52.
23. Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem. 2009;42:1046-50.
24. Kalantri Y, Naik G, Joshi SP, Jain A, Phatak S, Chavan R, Hemvani N. Chitnis DS Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions. Indian J Med Res. 2007;125:25-30.
25. Einhorn N, Sjovall K, Knapp RC, Hall P, Soully RE, Bast Jr RC, et al. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992;80:14-8.
26. Rubin J, Rockey DC. Cirrhotic ascites. Ovarian carcinoma and CA125. South Med J. 1999;92:248-50.
27. Trapé J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol. 2004;25:276-81.